{"filing":{"accession_number":"0001213900-26-077360","cik":"0001567529","ticker":"KMDA","company_name":"KAMADA LTD","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"ea0297771-6k_kamada.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567529/000121390026077360/ea0297771-6k_kamada.htm"},"events":[{"id":17490,"run_id":15666,"accession_number":"0001213900-26-077360","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit is a press release announcing positive clinical study results for CYTOGAM presented at the 2026 ISHLT Annual Meeting. The disclosure highlights investigator-initiated research demonstrating improved clinical outcomes in CMV high-risk lung transplant recipients receiving CMVIG prophylaxis, with mechanistic insights into immune modulation. While the results support increased product utilization and are strategically important to Kamada's commercial portfolio, this is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a material operational/commercial milestone—positive clinical validation of a marketed product—that would affect investor assessment of the product's market potential and the company's growth strategy.","company_name":"KAMADA LTD","ticker":"KMDA","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":[{"id":15988,"accession_number":"0001213900-26-077360","item_number":"EX-99.1","item_title":"ea029777101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing positive clinical study results for CYTOGAM presented at the 2026 ISHLT Annual Meeting. The disclosure highlights investigator-initiated research demonstrating improved clinical outcomes in CMV high-risk lung transplant recipients receiving CMVIG prophylaxis, with mechanistic insights into immune modulation. While the results support increased product utilization and are strategically important to Kamada's commercial portfolio, this is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a material operational/commercial milestone—positive clinical validation of a marketed product—that would affect investor assessment of the product's market potential and the company's growth strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:47:38.440152+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15988,"accession_number":"0001213900-26-077360","item_number":"EX-99.1","item_title":"ea029777101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing positive clinical study results for CYTOGAM presented at the 2026 ISHLT Annual Meeting. The disclosure highlights investigator-initiated research demonstrating improved clinical outcomes in CMV high-risk lung transplant recipients receiving CMVIG prophylaxis, with mechanistic insights into immune modulation. While the results support increased product utilization and are strategically important to Kamada's commercial portfolio, this is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a material operational/commercial milestone—positive clinical validation of a marketed product—that would affect investor assessment of the product's market potential and the company's growth strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:47:38.440152+00:00","company_name":"KAMADA LTD","ticker":"KMDA","filing_date":"2026-07-13"}]}